- $531.78m
- $212.84m
- 58
- 30
- 30
- 33
Annual balance sheet for Tyra Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 15.2 | 302 | 251 | 203 | 341 |
| Prepaid Expenses | |||||
| Total Current Assets | 15.3 | 304 | 257 | 212 | 347 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.466 | 2.09 | 3.54 | 8.15 | 7.72 |
| Other Long Term Assets | |||||
| Total Assets | 16 | 307 | 266 | 226 | 364 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.86 | 3.62 | 5.7 | 15.3 | 14.6 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2 | 4.96 | 8.35 | 21.6 | 20.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 14 | 302 | 258 | 204 | 343 |
| Total Liabilities & Shareholders' Equity | 16 | 307 | 266 | 226 | 364 |
| Total Common Shares Outstanding |